Could iodine be effective in the treatment of human immunodeficiency virus and AIDS-associated opportunistic infections?  by Mamo, John C.L. & Naissides, Mary
International Journal of Infectious Diseases (2005) 9, 292—293
http://intl.elsevierhealth.com/journals/ijidLETTER TO THE EDITORCould iodine be effective in the treatment of
human immunodeficiency virus and AIDS-asso-
ciated opportunistic infections?
Retroviruses share similarities in structure, geno-
mic organization and replication and are asso-
ciated with immunodeficiencies. AIDS describes
the most advanced stages of HIV infection and is
characterized by a progressive loss of the CD4+
helper subset of the T-lymphocytes resulting in
immune suppression, constitutional diseases and
opportunistic infections. The feline immunodefi-
ciency retrovirus (FIV) has a clinical pathology not
unlike that of HIV/AIDS, including AIDS-related
complexes and chronic immunodeficiency.1,2 In
an uncontrolled case study, it was found that an
adult cat diagnosed with end-stage FIV recovered
within eight weeks of treatment with a daily oral
gavage of a commercially available iodine solution
(tincture of iodine (2.5% w/v), 4 mg in 10 ml water,
three times daily). Moreover, for at least five years
there was no further clinical evidence of disease in
this cat. The animal’s recovery may have been due
to iodine’s broad spectrum therapeutic effect on
opportunistic infections, or possibly because of
suppression of viraemia.
In HIV and FIV infection, viral load is dependent
on the stage of infection, however it generally
predominates in cells of the reticulo-endothelial
system. Iodine is commonly prepared in two forms:
conjugated with a cation, which is soluble in aqu-
eous media, or complexed as two molecules which
has lipophilic properties. A number of studies have
demonstrated that iodine, and in particular the
lipophilic form, possesses potent antiviral and
microbiocidal properties in vitro.3,4 The triglycer-
ide-rich lipoproteins, including chylomicrons and
very low-density lipoproteins, serve as an energy
substrate for inflammatory cells. It is our contention
that the lipophilic form of iodine, when ingested
orally, may be particularly effective as a microbio-
cidal/antiviral agent, because it would be incorpo-
rated into chylomicrons, transported via the1201-9712/$30.00 # 2005 International Society for Infectious Diseas
doi:10.1016/j.ijid.2004.11.004lymphatic system and be delivered to the cells of
the reticulo-endothelial system.
A Folch extraction of the commercial preparation
of iodine used to treat the cat with FIV was carried
out in order to explore the relative abundance of the
lipophilic and hydrophilic form of iodine. The absor-
bance profiles of the aqueous and solvent phases
found that the iodine suspension contained both
forms, with a distribution of approximately one
third as the more potent antiviral lipophilic moiety.
Absorption and distribution of iodine was deter-
mined by isotopic tracer studies in lymph cannu-
lated and intact rodents. In cannulated rats, lymph
delivery of iodine peaked at approximately 2 hours
following infusion of iodine into the duodenum (see
Figure 1) and was complete after 6 hours. Analysis of
the chylomicron versus non-lipoprotein fraction of
lymph found that iodine was distributed essentially
equally (Figure 1).
Plasma iodine concentration following adminis-
tration by oral gavage to intact animals, showed a
rapid phase of delivery (<10 min) presumably as
unbound iodine and thereafter, at increasing con-
centrations associated with plasma lipoproteins
(Figure 1). The tissue distribution of iodine was
determined 4 hours post gavage in intact animals.
It was found that concentration was greatest in the
spleen per unit weight of tissue and some 1.6-fold
greater than in thyroid, liver or muscle tissue.
Inhibiting opportunistic infections or viral load
may reduce or prevent some of the clinical mani-
festations associated with retroviral infections.
Incorporating microbiocidal compounds into trigly-
ceride-rich lipoproteins may enhance delivery to
cells harboring bacteria and viruses. The authors’
pilot studies suggest that using a common prepara-
tion of iodine, significant quantities of the lipophilic
form were incorporated into chylomicrons and
delivered to cells of the reticulo-endothelial sys-
tem. Based on the relative distribution of iodine
found in plasma and lymph (i.e. as a percentage of
the dose administered), concentrations known to be
effective in vitro could be readily achieved by orales. Published by Elsevier Ltd. All rights reserved.
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Figure 1 Approximately 4 mg of radiolabelled iodine
suspended in water was given by oral gavage and the
concentration in plasma determined. In lymph-cannu-
lated animals, iodine was introduced via a cannula placed
directly into the duodenum. Data are expressed as a
percentage of the dose given. CM = lymph chylomicron.ingestion. These observations are presented in the
context of hypothesis generation and have not con-
sidered different iodine preparations, species or the
dose of iodine administered. Of particular interest
would be the putative effects of iodine preparations
in modulating viral load, which need to be explored
in animal models at different stages of disease.
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